Dr Floyd A Richard, MD | |
2201 Murphy Ave, Ste 411, Nashville, TN 37203-1888 | |
(615) 321-3605 | |
(615) 321-3629 |
Full Name | Dr Floyd A Richard |
---|---|
Gender | Male |
Speciality | Obstetrics/gynecology |
Experience | 43 Years |
Location | 2201 Murphy Ave, Nashville, Tennessee |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1063416592 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | 13552 (Tennessee) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Pediatrix Medical Group Of Tennessee, P.c. | 2668538265 | 7 |
News Archive
High-dose sublingual immunotherapy effectively reduces allergic symptoms and medication use in children with grass pollen–allergic rhinoconjunctivitis, show study results.
Novartis announced today that the European Commission approved once-daily Ultibro® Breezhaler® (indacaterol 85 mcg / glycopyrronium 43 mcg) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). In addition, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro® Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro® Breezhaler® / Ultibro® Inhalation Capsules were developed under the name QVA149.
Pancreatic cancer has an extremely poor prognosis; it is the third most common cause of cancer deaths in the United States.
As British cyclist Chris Froome celebrates his third Tour de France victory, research from the University of Kent and Australian collaborators shows for the first time that elite endurance athletes have superior ability to resist mental fatigue.
› Verified 2 days ago
Entity Name | Pediatrix Medical Group Of Tennessee, P.c. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1497852107 PECOS PAC ID: 2668538265 Enrollment ID: O20090305000758 |
News Archive
High-dose sublingual immunotherapy effectively reduces allergic symptoms and medication use in children with grass pollen–allergic rhinoconjunctivitis, show study results.
Novartis announced today that the European Commission approved once-daily Ultibro® Breezhaler® (indacaterol 85 mcg / glycopyrronium 43 mcg) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). In addition, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro® Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro® Breezhaler® / Ultibro® Inhalation Capsules were developed under the name QVA149.
Pancreatic cancer has an extremely poor prognosis; it is the third most common cause of cancer deaths in the United States.
As British cyclist Chris Froome celebrates his third Tour de France victory, research from the University of Kent and Australian collaborators shows for the first time that elite endurance athletes have superior ability to resist mental fatigue.
› Verified 2 days ago
Entity Name | Richard & Carter M.d. P.c. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1417170341 PECOS PAC ID: 1759570807 Enrollment ID: O20110105000959 |
News Archive
High-dose sublingual immunotherapy effectively reduces allergic symptoms and medication use in children with grass pollen–allergic rhinoconjunctivitis, show study results.
Novartis announced today that the European Commission approved once-daily Ultibro® Breezhaler® (indacaterol 85 mcg / glycopyrronium 43 mcg) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). In addition, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro® Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro® Breezhaler® / Ultibro® Inhalation Capsules were developed under the name QVA149.
Pancreatic cancer has an extremely poor prognosis; it is the third most common cause of cancer deaths in the United States.
As British cyclist Chris Froome celebrates his third Tour de France victory, research from the University of Kent and Australian collaborators shows for the first time that elite endurance athletes have superior ability to resist mental fatigue.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Floyd A Richard, MD 2201 Murphy Ave, Ste 411, Nashville, TN 37203-1888 Ph: (615) 321-3605 | Dr Floyd A Richard, MD 2201 Murphy Ave, Ste 411, Nashville, TN 37203-1888 Ph: (615) 321-3605 |
News Archive
High-dose sublingual immunotherapy effectively reduces allergic symptoms and medication use in children with grass pollen–allergic rhinoconjunctivitis, show study results.
Novartis announced today that the European Commission approved once-daily Ultibro® Breezhaler® (indacaterol 85 mcg / glycopyrronium 43 mcg) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). In addition, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro® Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro® Breezhaler® / Ultibro® Inhalation Capsules were developed under the name QVA149.
Pancreatic cancer has an extremely poor prognosis; it is the third most common cause of cancer deaths in the United States.
As British cyclist Chris Froome celebrates his third Tour de France victory, research from the University of Kent and Australian collaborators shows for the first time that elite endurance athletes have superior ability to resist mental fatigue.
› Verified 2 days ago
Barbara H Nylander, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 345 23rd Ave N, Suite 209, Nashville, TN 37203 Phone: 615-329-9082 Fax: 615-329-2423 | |
Dr. Vernita Ann Tucker, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1005 Dr. D. B. Todd Blvd, Nashville, TN 37208 Phone: 615-327-5524 Fax: 615-327-5541 | |
Alexandra Jordan Douglas Phelps, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-936-2000 | |
Douglas H Brown, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 300 20th Ave N Ste 302, Nashville, TN 37203 Phone: 615-284-2988 Fax: 615-284-2995 | |
Barry S Grimm, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
Shannon Marie Madison, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2011 Murphy Ave Ste 601, Nashville, TN 37203 Phone: 615-329-6622 Fax: 615-329-6785 | |
Mckenzie Diane Canon, APRN Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-5000 |